352 related articles for article (PubMed ID: 24425689)
21. Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway.
Tang LA; Dixon BN; Maples KT; Poppiti KM; Peterson TJ
Pharmacotherapy; 2018 Oct; 38(10):1058-1067. PubMed ID: 30120858
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K signaling pathway in cancer therapy.
Bartholomeusz C; Gonzalez-Angulo AM
Expert Opin Ther Targets; 2012 Jan; 16(1):121-30. PubMed ID: 22239433
[TBL] [Abstract][Full Text] [Related]
23. The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
Seiler T; Hutter G; Dreyling M
Drugs; 2016 Apr; 76(6):639-46. PubMed ID: 27052260
[TBL] [Abstract][Full Text] [Related]
24. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
25. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
Höland K; Salm F; Arcaro A
Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
[TBL] [Abstract][Full Text] [Related]
26. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
28. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
Kwong LN; Davies MA
Clin Cancer Res; 2013 Oct; 19(19):5310-9. PubMed ID: 24089444
[TBL] [Abstract][Full Text] [Related]
29. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
30. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Martelli AM; Chiarini F; Evangelisti C; Cappellini A; Buontempo F; Bressanin D; Fini M; McCubrey JA
Oncotarget; 2012 Apr; 3(4):371-94. PubMed ID: 22564882
[TBL] [Abstract][Full Text] [Related]
31. Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications.
Arcaro A
Autophagy; 2013 Apr; 9(4):607-8. PubMed ID: 23324613
[TBL] [Abstract][Full Text] [Related]
32. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
33. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
34. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
35. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G; Shah RR
Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
[TBL] [Abstract][Full Text] [Related]
36. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Zhu J; Hou T; Mao X
Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Foster JG; Blunt MD; Carter E; Ward SG
Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
[TBL] [Abstract][Full Text] [Related]
38. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Wee S; Lengauer C; Wiederschain D
Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Janku F
Cancer Treat Rev; 2017 Sep; 59():93-101. PubMed ID: 28779636
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K signaling pathway in cancer.
Wong KK; Engelman JA; Cantley LC
Curr Opin Genet Dev; 2010 Feb; 20(1):87-90. PubMed ID: 20006486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
